COVID-SAFER:老年人羟氯喹药物相互作用的减处方指导
该研究重新分析MedSafer试点研究中65岁及以上住院患者队列,评估与羟氯喹潜在有害相互作用的家庭用药及潜在不适当药物负担。共纳入1001例患者,590例(58.9%)使用至少一种可能相互作用的药物,其中255例(43.2%)被MedSafer标记为潜在不适当。作者据此提出COVID-19治疗考量下的用药管理指导。
要点
- 58.9%的老年住院患者使用可能与他羟氯喹相互作用的家庭药物。
- 43.2%的相互作用药物被MedSafer标记为潜在不适当。
- 常见潜在不适当药物包括抗精神病药、心血管药和降糖药。
核心结论
- COVID-19大流行凸显优化老年患者用药和减处方潜在不适当药物的重要性。
- 减少多重用药和潜在不适当药物使用可为老年患者参与试验及可能的药物治疗或预防做好准备。
研究设计与样本
- 重新分析MedSafer试点研究中65岁及以上住院患者队列的数据。
- 共纳入1001例拥有完整入院前家庭用药数据的独特患者。
主要发现
- 1001例患者中590例(58.9%)使用一种或多种可能与羟氯喹相互作用的家庭药物。
- 590例中255例(43.2%)的药物被MedSafer工具标记为潜在不适当。
- 常见潜在不适当药物类别为抗精神病药、心血管药物和降糖药。
关键数值与推荐
- 与羟氯喹潜在有害药物相互作用可能导致患者被排除在典型COVID-19治疗试验之外。
- MedSafer标记的潜在不适当药物需在考虑使用羟氯喹时进行用药管理指导。
临床怎么用
- 对老年患者考虑羟氯喹治疗前应评估家庭用药中的相互作用和潜在不适当药物。
- 通过减处方潜在不适当药物和减少多重用药优化用药方案。
局限性
- 本研究为对MedSafer试点研究队列的重新分析,非前瞻性干预研究。
- 仅基于入院前家庭用药数据,未报告随访或临床结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/OBJECTIVES: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causes high morbidity and mortality in older adults with chronic illnesses. Several trials are currently underway evaluating the antimalarial drug hydroxychloroquine as a potential treatment for acute infection. However, polypharmacy predisposes patients to increased risk of drug-drug interactions with hydroxychloroquine and may render many in this population ineligible to participate in trials. We aimed to quantify the degree of polypharmacy and burden of potentially inappropriate medications (PIMs) that older hospitalized adults are taking that would interact with hydroxychloroquine. METHODS: We reanalyzed data from the cohort of patients 65 years and older enrolled in the MedSafer pilot study. We first identified patients taking medications with potentially harmful drug-drug interactions with hydroxychloroquine that might exclude them from participation in a typical 2019 coronavirus disease (COVID-19) therapeutic trial. Next, we identified medications that were flagged by MedSafer as potentially inappropriate and crafted guidance around medication management if contemplating the use of hydroxychloroquine. RESULTS: The cohort contained a total of 1,001 unique patients with complete data on their home medications at admission. Of these 1,001 patients, 590 (58.9%) were receiving one or more home medications that could potentially interact with hydroxychloroquine, and of these, 255 (43.2%) were flagged as potentially inappropriate by the MedSafer tool. Common classes of PIMs observed were antipsychotics, cardiac medications, and antidiabetic agents. CONCLUSION: The COVID-19 pandemic highlights the importance of medication optimization and deprescribing PIMs in older adults. By acting now to reduce polypharmacy and use of PIMs, we can better prepare this vulnerable population for inclusion in trials and, if substantiated, pharmacologic treatment or prevention of COVID-19. J Am Geriatr Soc 68:1636-1646, 2020.
引用
- Ross SB, Wilson MG, Papillon-Ferland L, et al. COVID-SAFER: Deprescribing Guidance for Hydroxychloroquine Drug Interactions in Older Adults. J Am Geriatr Soc. 2020. PMID: 32441771. doi:10.1111/jgs.16623
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。